Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant human ALK-1/ACVRL1 Protein, 1mg  

Recombinant human ALK-1/ACVRL1 Protein, 1mg

Recombinant human ALK-1 /ACVRL1 Protein (rhALK1), Asp22-Gln118 was expressed in human 293 cells (HEK293)

Synonym
recombinant, human, protein ACVRL1, ACVRL-1, ACVRLK1, ALK-1, ALK1, HHT, HHT2, HHT-2, ORW2, ORW-2, SKR3, SKR-3, TSR-I

More details

AL1-H5227-1K

Availability: within 7 days

1 800,00 €

Background
Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene[1-2]. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic [3]. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells[4].

Source
Recombinant human ALK-1 /ACVRL1 Protein (rhALK1), Asp22-Gln118 (Accession # NP_000011.2) was expressed in human 293 cells (HEK293)

Molecular Characterization
rhALK1, a 108 amino acids protein with polyhistidine tag at C-terminus, and has a calculated MW of 12.3 kDa. The predicted N-terminus is Asp22. DTT-reduced protein migrates as 26 kDa protein due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the rhALK1 by the LAL method.

Purity
>97% purity as determined by SDS-PAGE of reduced rhALK1.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
N/A

References

(1) Ten Dijke P, Ichijo H, et al. (Oct 1993). Oncogene 8 (10): 2879–87
(2) Johnson DW, Berg JN, et al.(Jul 1996). Nat Genet 13 (2): 189–95
(3) Lawlor MW, Read BP, et al. (Feb.2011). Am J Pathol. 178(2):784-93
(4) Mitchell D,et al.(Feb. 2010). Mol Cancer Ther.. 9(2):379-88